Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.51 |
| ▸ | TAF1 | P21675 | 3/20 | 0.51 |
| ▸ | CECR2 | Q9BXF3 | 3/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.49 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17749037 | 0.86 | LIMK2 (0.49) | BRD4GPR119JAK1JAK2TYK2 | |
| SCHEMBL19639663 | 0.78 | KDM4E (0.46) | GPR119JAK1JAK2TYK2JAK3 | |
| Hydrochloric Acid SCHEMBL17749013 | 0.78 | TAF1 (0.51) | BRD4TAF1CECR2BRD9PARP1 | |
| SCHEMBL9943184 | 0.74 | USP30 (0.75) | GPR119USP30MEN1KMT2A | |
| SCHEMBL3036553 | 0.73 | USP30 (0.64) | GPR119USP30MEN1KMT2A | |
| SCHEMBL28628584 | 0.73 | USP30 (0.67) | GPR119USP30 | |
| SCHEMBL17748965 | 0.72 | JAK1 (0.41) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL388120 | 0.72 | GPR119 (0.69) | GPR119USP30 | |
| SCHEMBL28632797 | 0.72 | MEN1 (0.67) | GPR119USP30MEN1KMT2A | |
| SCHEMBL28651615 | 0.71 | GPR119 (0.74) | GPR119USP30MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108613-B | Bromodomain inhibitors and uses thereof | 基因泰克公司 | 2020-02-25 | — | — | CN | disclosed |
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | BRD4 1/4885TAF1 439/4885CECR2 184/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | BRD4 1/4885TAF1 439/4885CECR2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.